Current approaches to the management of pediatric hodgkin lymphoma

Pediatric Drugs

Volumn 12, Issue 2, 2010, Pages 85-98

  Freed, Jennifer ^a   Kelly, Kara M ^b  

^a BROOKLYN HOSPITAL CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Alkylating agents, therapeutic use; Anthracyclines, therapeutic use; Bleomycin, therapeutic use; Bortezomib, therapeutic use; Brentuximab vedotin, therapeutic use; Children; Chlormethine, therapeutic use; Cisplatin, therapeutic use

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BLEOMYCIN; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GYRASE INHIBITOR; IFOSFAMIDE; IRATUMUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MDX 060; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; NAVELBINE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RAZOXANE; RITUXIMAB; SGN 30; SGN 35; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; AZOOSPERMIA; CANCER MORTALITY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; CATARACT; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; HEART ARRHYTHMIA; HEART DISEASE; HEART LEFT VENTRICLE DYSFUNCTION; HODGKIN DISEASE; HUMAN; HYPOGONADISM; INFERTILITY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OSTEOPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; PERCEPTION DEAFNESS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION INJURY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTINEOPLASTIC AGENTS; CHILD; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; REMISSION INDUCTION; RISK FACTORS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 77949443141     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11316170-000000000-00000     Document Type: Review

References (73)

1. National Cancer Institute. Cancer stat fact sheets: Hodgkin lymphoma. Surveillance Epidemiology and End Results (SEER) [online]. Available from URL: http://seer.cancer.gov/statfacts/html/hodg.html [Accessed 2008 Apr 9]
2. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7 (11): 1630-1636
3. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-1514
4. Smith RS, Chen Q, Hudson MM, et al. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol 2003 May; 21 (10): 2026-2033
5. Hodgson D, HudsonM, Constine L. Pediatric Hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Semin Radiat Oncol 2007; 17: 230-242
6. ClinicalTrials.gov, a service of the US National Institutes of Health. Combination chemotherapy followed by radiation therapy in treating young patients with newly diagnosed Hodgkin's lymphoma (NCT00302003) [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/ NCT00302003?term= NCT00302003&rank=1 [Accessed 2008 May 24]
7. Clinical Trials.gov, a service of the US National Institutes of Health. Chemotherapy with or without additional chemotherapy and/or radiation therapy in treating children with newly diagnosed Hodgkin's disease (NCT00025259) [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/ NCT00025259?term=NCT00025259&rank=1 [Accessed 2008 May 24]
8. ClinicalTrials.gov, a service of the US National Institutes of Health. Combination chemotherapy and radiation therapy in treating young patients with newly diagnosed Hodgkin lymphoma (NCT01026220) [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT01026220?term= AHOD0831&rank=1 [Accessed 2010 Jan 2]
9. Schellong G, Potter R, Bramswig J, et al. High cure rates and reduced longterm toxicity in pediatric Hodgkin's disease: the German-Austrian Multicenter Trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999 Dec; 17 (12): 3736-3744
10. Ruhl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 Trial. Int J Radiation Oncology Biol Phys 2001; 51 (5); 1209-1218
11. Donaldson S, LinkM,Weinstein H, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with lowrisk Hodgkin's disease. J Clin Oncol 2007; 25: 332-337
12. Hudson M, Krasin M, Link M, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol 2004; 22: 4541-4550
13. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2- deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007 Aug; 25 (24): 3746-3752
14. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy: results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000; 18 (7): 1500-1507
15. Nachman J, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20 (18): 3765-3771
16. Tebbi CK, Mendenhall N, London WB, et al. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine, and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 2006; 46: 198-202
17. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004; 22: 62-68
18. Arya L, Dinand V, Thavaraj V, et al. Hodgkin's disease in Indian children: outcome with chemotherapy alone. Pediatr Blood Cancer 2006; 46: 26-34
19. Hakvoort-Cammel F, Buitendijk S, Van Den Heuvel-Eibrink M, et al. Treatment of Pediatric dodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-Protocol. Pediatr Blood Cancer 2004; 43: 8-16
20. Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach usingABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 2009; 114: 2051-2059
21. Tebbi CK, London WB, Freidmann D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007; 25: 493-500
22. KarayalcinG, Behm FG, Gieser PW, et al. Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment. The Pediatric Oncology Group experience. Med Pediatr Oncol 1997; 29: 519-525
23. Sandoval C, Venkateswaran L, Billups C, et al. Lymphocyte-predominant Hodgkin disease in children. J Ped Heme/Onc 2002; 24: 269-273
24. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte- predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection. A study of the French Society of Pediatric Oncology. J Clin Oncol 2003; 21: 2948-2952
25. Murphy SB, Morgan ER, Katzenstein HM, et al. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol 2003; 25: 684-687
26. ClinicalTrials.gov, a service of the US National Institutes of Health. Treating young patients with newly diagnosed, low stage, lymphocyte predominant Hodgkin's disease (NCT0010719) [online] Available from URL: http://www. clinicaltrials.gov/ct2/show/NCT00107198?term=NCT00107198&rank=1 [Accessed 2008 May 24]
27. Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront doseintensive chemotherapy in children with advanced-stageHodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704. Ann Oncol 2002; 13 Suppl. 1: 107-111
28. Weiner MA, Leventhal B, Brecher ML, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients.APediatric Oncology Group study. J Clin Oncol 1997; 15 (8): 2769-2779
29. ClinicalTrials.gov, a service of the US National Institutes of Health. Combination chemotherapy in treating young patients with Hodgkin's lymphoma (NCT00433459) [online]. Available from URL: http://www.clinicaltrials. gov/ct2/show/NCT00433459?term=NCT00433459&rank=1 [Accessed 2008 Jun 3]
30. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin disease after combination chemotherapy: the low probability of cure. JClin Oncol 1992; 10: 210-218
31. Viviani S, Santoro A, Negretti E, et al. Salvage chemotherapy in Hodgkin disease: results in patients relapsing more than twelve months after first complete remission. Ann Oncol 1990; 1: 123-127
32. David K, Mauro L, Evens AM. Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options. Curr Treat Options Oncol 2007; 8: 352-374
33. Josting A, Franklin J, MayM, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2002; 20: 221-230
34. Bierman PJ, Lynch JC, Bociek RG, et al. The International Prognostic Factors Project Score for advanced Hodgkin's disease is useful for predicting outcome of autologous stem cell transplantation. Ann Oncol 2002; 13: 1370-1377
35. Schellong G, Dorffel W, Claviez A, et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the Pediatric DAL/GPOH-HD Study Group. J Clin Oncol 2005; 23 (25): 6181-6189
36. Lieskovsky YE, Donaldson SS, Torres MA, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. J Clin Oncol 2004; 22: 4532-4540
37. Kobrinsky N, Sposto R, Shah N, et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and L-asparaginase, maintenance chemotherapy, and transplantation. Children's Cancer Group Study CCG-5912. J Clin Oncol 2001; 19: 2390-2396
38. Cole PD, Schwartz CL, Drachtman RA, et al. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. J Clin Oncol 2009; 27: 1456-1461
39. ClinicalTrials.gov, a service of the US National Institutes of Health. Gemcitabine and vinorelbine in treating young patients with recurrent or refractory Hodgkin's lymphoma (NCT00070304) [online]. Available from URL: http:// www.clinicaltrials.gov/ct2/show/NCT00070304?term=NCT00070304&rank=1 [Accessed 2008 Jun 18]
40. Linch DC, Goldstone AH, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054
41. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stemcell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-2071
42. Schmitz N, Haverkamp H, Josting A, et al. Long term follow up in relapsed Hodgkin's disease (HD): updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoietic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT) [abstract no. 6508]. J Clin Oncol 2005; 23 Suppl.: 562S
43. Peniket AJ, Elvira MCRd, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedurerelated mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667-678
44. ClinicalTrials.gov, a service of the US National Institutes of Health (NCT00057954) [online]. Available from URL: http://www.clinicaltrials.gov/ ct2/show/NCT00057954?term=NCT00057954&rank=1. [Accessed 2008 Jun 18]
45. ClinicalTrials.gov, a service of the US National Institutes of Health (NCT00697684) [online]. Available from URL: http://www.clinicaltrials. gov/ct2/show/NCT00697684?term=NCT00697684&rank=1 [Accessed 2008 Jun 18]
46. ClinicalTrials.gov, a service of the US National Institutes of Health (NCT00385788) [online]. Available from URL: http://www.clinicaltrials. gov/ct2/show/NCT00385788?term=NCT00385788&rank=1 [Accessed 2008 Jun 18]
47. Leonard JP, Rosenblatt JD, Bartlett NL, et al. Phase II study of SGN-30 (anti- CD30 monoclonal antibody) in patients with refractory or recurrent Hodgkin's disease. ASH Annual Meeting Abstracts 2004; 104: 2635
48. Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30 + hematologic malignancies. Blood 2008; 111 (4): 1848-1854
49. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25 (19): 2764-2769
50. Younes A, Forero-TorresA, Bartlett N, et al.Anovel antibody-drug conjugate, SGN-35 (anti-CD30-Auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma: preliminary results of a phase I tolerability study [abstract no. P099]. Haematologica 2007; 92 Suppl. 5: 64
51. Schnell R, Dietlein M, Staak JO, et al. Treatment of refractory Hodgkin's lymphoma with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005; 23 (21): 4669-4678
52. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte- predominant Hodgkin Lymphoma: long-term results of a phase-II trial of theGerman Hodgkin Lymphoma StudyGroup (GHSG). Blood 2008; 111 (1): 109-111
53. O'Mahony D, Janik JE, Carrasquillo JA, et al. Yttrium-90 radiolabeled humanized anti-CD25 monoclonal antibody, daclizumab, provides effective therapy for refractory and relapsed Hodgkin's lymphoma [abstract no. 1060]. Haematologica 2007; 92 Suppl. 5: 18
54. Karin M, Cao Y, Greten F, et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-310
55. Li X, Stark GR. NFkappaB-dependent signaling pathways. Exp Hematol 2002; 30: 285-296
56. Blum KA, Johnson JL, Niedzwiecki D, et al. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma 2007; 48 (7): 1313-1319
57. ClinicalTrials.gov, a service of the US National Institutes of Health (NCT00381940) [online]. Available from URL: http://www.clinicaltrials. gov/ct2/show/NCT00381940?term=NCT00381940&rank=1 [Accessed 2008 Jun 3]
58. Younes A, Fanale M, Pro B, et al. A phase II study of a novel oral isotypeselective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma [abstract no. 8000]. J Clin Oncol 2007; 25 Suppl.: 441S
59. Donaldson SS, Kaplan HS. Complications of treatment of Hodgkin's disease in children. Cancer Treat Rep 1982; 66: 977-989
60. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 2007; 25 Suppl.: 441S
61. Chow LML, Nathan PC, Hodgson DC, et al. Survival and late effects in children with Hodgkin's lymphoma treated with MOP/ABV and low-dose, extended-field irradiation. J Clin Oncol 2006; 24: 5735-5741
62. Kremer LCM, van Dalen EC, OffringaM, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001; 19: 191-196
63. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in fiveyear survivors of childhood cancer: Childhood Cancer Survivor Study. J Natl Cancer Inst 2001; 93: 618-629
64. Bhatia S, Robison LL, Meadows AT, et al. High risk of second malignant neoplasms (SMN) continueswith extended follow-up of childhood Hodgkin's disease (HD) cohort: report from the Late Effects Study Group [abstract]. Blood 2001; 98: 768a
65. SigurdsonAJ, Ronckers CM, Mertens AC, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 2005; 365: 2014-2023
66. Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin's disease. N Engl J Med 1990; 322: 7-13
67. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000; 85: 3227-3232
68. Thomson AB, Wallace WH, Sklar C. Testicular function. In: Wallace WH, Green DM, editors. Late effects of childhood cancer. London: Arnold, 2004: 239-256
69. Mackie EJ,Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin's disease. Med Pediatr Oncol 1996; 7: 74-78
70. Critchley HO, Thomson AB, Wallace WH. Ovarian and uterine function and reproductive potential. In: Wallace WH, Green DM, editors. Late effects of childhood cancer. London: Arnold, 2004: 225-238
71. Horning SJ, Hoppe RT, Kaplan HS. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med 1981; 304: 1377-1381
72. Bokemeyer C, Schmoll HJ, van Rhee J, et al. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Ann Hematol 1994; 68: 105-110
73. Byrne J, Fears TR, Gail MH. Early menopause in long-term survivors of cancer during adolescence. Am J Obstetr Gynecol 1992; 166: 788-793